Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 15/20 | 0.38 |
| ▸ | ABL1 | P00519 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19669952 | 0.88 | POLB (0.41) | MAP4K1ABL1 | |
| SCHEMBL19365728 | 0.85 | HDAC2 (0.43) | ABL1 | |
| SCHEMBL19670240 | 0.85 | PRMT5 (0.37) | — | |
| SCHEMBL19365331 | 0.84 | HDAC2 (0.37) | ABL1 | |
| SCHEMBL19670417 | 0.83 | MAP4K1 (0.42) | MAP4K1ABL1 | |
| SCHEMBL19365727 | 0.83 | ATM (0.37) | MAP4K1ABL1 | |
| SCHEMBL19670239 | 0.82 | MAP4K1 (0.41) | MAP4K1ABL1 | |
| SCHEMBL19670526 | 0.82 | MAP4K1 (0.41) | MAP4K1ABL1 | |
| SCHEMBL19670415 | 0.81 | ABL1 (0.46) | MAP4K1ABL1 | |
| SCHEMBL19365429 | 0.81 | POLB (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | MAP4K1 2341/4885ABL1 4089/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | MAP4K1 2341/4885ABL1 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.